Guanylyl Cyclase alpha 2 (GUCY1A2) Antibody (N-term) Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P33402 |
---|---|
Clone Names | 5030103 |
Gene ID | 2977 |
---|---|
Other Names | Guanylate cyclase soluble subunit alpha-2, GCS-alpha-2, GUCY1A2, GUC1A2, GUCSA2 |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP7133a was selected from the N-term region of human GUCY1A2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | GUCY1A2 |
---|---|
Synonyms | GUC1A2, GUCSA2 |
Function | Has guanylyl cyclase on binding to the beta-1 subunit. |
Cellular Location | Cytoplasm. |
Tissue Location | Isoform 1 is expressed in fetal brain, liver, colon, endothelium and testis. Isoform 2 is expressed only in liver, colon and endothelium |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Soluble guanylate cyclase (sGC), a heterodimeric protein consisting of an alpha and a beta subunit, catalyzes the conversion of GTP to the second messenger cGMP and functions as the main receptor for nitric oxide and nitrovasodilator drugs.
References
Baba, H., et al., Neuroreport 15(4):677-680 (2004).Bellamy, T.C., et al., Proc. Natl. Acad. Sci. U.S.A. 99(1):507-510 (2002).Russwurm, M., et al., J. Biol. Chem. 276(48):44647-44652 (2001).Bamberger, A.M., et al., J. Clin. Endocrinol. Metab. 86(2):909-912 (2001).Budworth, J., et al., Biochem. Biophys. Res. Commun. 263(3):696-701 (1999).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.